Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review

Human Vaccines & Immunotherapeutics, Год журнала: 2025, Номер 21(1)

Опубликована: Март 13, 2025

This systematic literature review summarizes the evidence across 56 publications and pre-prints (January 2020–July 2023) with low-risk of bias based on JBI critical appraisal, that report adjusted estimates for relationship between COVID-19 vaccination Post-COVID-19 Condition (PCC) by timing relative to infection or PCC-onset. Comparisons vaccine effectiveness (aVE) against ≥1 PCC (vs. unvaccinated) study characteristics known impact burden VE other endpoints were possible 31 studies where preceded infection. Seventy-seven percent pre-infection aVE statistically significant (range: 7%–95%). Statistically slightly higher mRNA 14%–84%) than non-mRNA vaccines 16%–38%) ranges before during Omicron overlapped. Our findings suggest SARS-CoV-2 reduces risk regardless type, number doses received, definition, predominant variant, severity acute infections included.

Язык: Английский

---

Management of SARS-CoV-2 Infection-Clinical Practice Guidelines of the Polish Association of Epidemiologists and Infectiologists, for 2025

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(7), С. 2305 - 2305

Опубликована: Март 27, 2025

The first Polish recommendations for the management of COVID-19 were published by Society Epidemiologists and Infectiologists (PTEiLChZ) on 31 March 2020, last three years ago. emergence new SARS-CoV-2 variants, a different course disease, as well knowledge about therapies vaccines, requires updating diagnostic, therapeutic, prophylactic guidelines. Despite reduction in threat associated with COVID-19, there is risk another epidemic caused coronaviruses, which was an additional reason developing version In preparing these recommendations, Delphi method used, reaching consensus after survey cycles. Compared to 2022 version, names individual stages disease have been changed, adapting them realities clinical practice, attention paid differences observed immunosuppressed patients children. Some previously recommended drugs discontinued, including monoclonal antibodies. addition, general principles vaccination presented, issues related post-COVID syndrome.

Язык: Английский

---

The gut microbiome in post-COVID syndrome patients

The Innovation Medicine, Год журнала: 2025, Номер unknown, С. 100123 - 100123

Опубликована: Янв. 1, 2025

<p>Post-COVID syndrome (PCS) is a debilitating condition that affects significant number of COVID-19 survivors worldwide. PCS characterized by persistent symptoms such as fatigue, shortness breath, cognitive impairment, and gastrointestinal issues. The frequent occurrence has prompted researchers to investigate the role gut microbiota in development progression PCS. This review synthesizes findings from recent studies, providing comprehensive overview changes both patients patients. Evidence suggests can cause lasting alterations microbiota, marked reduced microbial diversity, an increase opportunistic pathogens, decrease beneficial bacteria support immune metabolic health. In addition, host-microbe interactions gut-lung, gut-brain, gut-heart axes are explored understand impact microbes on systemic Finally, potential diagnostic therapeutic strategies for discussed, including use probiotics, prebiotics, fecal transplantation (FMT) restore balance alleviate symptoms.</p>

Язык: Английский

---

Challenges and Opportunities for Post-COVID Pulmonary Disease: A Focused Review of Immunomodulation

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(8), С. 3850 - 3850

Опубликована: Апрель 18, 2025

The resolution of the recent COVID-19 pandemic still requires attention, since consequences having suffered infection, even in mild cases, are associated with several acute and chronic pathological conditions referred to as post-COVID syndrome (PCS). PCS often manifests pulmonary disease and, up 9% a more serious complication known post-COVID-19 fibrosis (PC19-PF), which has similar clinical course idiopathic (IPF). Generating knowledge provide robust evidence about benefits different therapeutic strategies treat effects can new insights amplify options for these patients. We present found after scoping review, following extended PRIMSA guidelines, use immunomodulators PCS. start brief description immunomodulatory properties relevant drugs, their clinically proven efficacy viral infections inflammatory conditions, during pandemic. emphasize need well-designed trials improve our understanding physiopathology PC19-PF also determine safety candidate treatments.

Язык: Английский

---

Long Covid Symptom Clusters, Correlates and Predictors in a Highly Vaccinated Australian Population in 2023

Health Expectations, Год журнала: 2025, Номер 28(3)

Опубликована: Май 8, 2025

ABSTRACT Background Limited data exists regarding long Covid burden following Omicron infection in highly vaccinated populations. Objective To (1) characterise prevalence and predictors (2) identify key symptom clusters their correlates among patients, during an Omicron‐predominant period a population. Design Anonymous, online, cross‐sectional survey. Setting January 2023, Australia. Participants Residents aged ≥ 18 years with self‐reported history of test‐positive Covid‐19. The main variables studied were socio‐demographic characteristics, Covid‐19 risk factors, vaccination, experiences Covid. Main Outcome Measures Long symptoms. Symptom‐based clustering was used to functional correlates. Predictors occurrence severity assessed using multivariable logistic regression. Results Overall, 240/1205 participants (19.9%) reported significantly higher for women OR 1.71 (95% CI: 1.17–2.51), people comorbidities 2.19 1.56–3.08) those steroid inhalers treatment (2.34 [95% 1.29–4.24]). Long‐Covid increased increasing (moderately severe symptoms: 2.23 1.50–3.30], extremely 5.80 3.48–9.66], presented ED/hospitalised: 7.22 3.06–17.03]). We found no significant difference the likelihood between pre‐Omicron periods, vaccination status participant age. identified two (pauci‐symptomatic, n = 170, vs. polysymptomatic, 66). Polysymptomatic cluster membership associated worse functioning (impacts on work, moderate activity, emotions energy). Severity acute strongly predictive polysymptomatic (5.72 [2.04–17.58]). Monoclonal antibody pauci‐symptomatic (0.02 [0.00–0.13]). Discussion Our study shows that is important health Australia, including era, identifies several factors. subgroup patients characterised by more symptoms outcomes. findings can inform policies protecting vulnerable populations frameworks assessment management. Conclusions One‐in‐five may suffer after infection, similar across age groups. variants appear not have lower compared earlier our study. A cumulative number help triage patients. Patient or Public Contribution did involve public design questionnaire. However, soft launch, we revised some survey questions reviewing early responses from public.

Язык: Английский

---

Long COVID: A Systematic Review of Preventive Strategies

Infectious Disease Reports, Год журнала: 2025, Номер 17(3), С. 56 - 56

Опубликована: Май 21, 2025

Background: Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, long COVID (LC) has become a significant global health burden. While knowledge about LC is accumulating, studies on its prevention are still lacking. Methods: We conducted systematic review following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to investigate options LC. identified fifteen articles vaccines, seven antivirals, six other interventions after searching PubMed/MEDLINE database using MeSH terms. Results: Most vaccine-related demonstrated protective effect COVID-19 vaccines against developing Our found an equivocal while metformin had outpatients corticosteroids were hospitalized patients Conversely, convalescent plasma multiple micronutrient supplement did not confer any protection Conclusions: vaccination vital as it only prevents but also reduces severity illness may help prevent Further warranted shed light preventive strategies COVID.

Язык: Английский

---

Estimating long COVID-19 prevalence across definitions and forms of sample selection

Frontiers in Epidemiology, Год журнала: 2025, Номер 5

Опубликована: Май 30, 2025

Introduction Long COVID (LC) is a multisystem condition with prolonged symptoms persisting beyond acute SARS-CoV-2 infection. However, prevalence estimates vary widely due to differences in case definitions and sampling methodologies. This study aims determine the of LC across different correct for selection bias using advanced statistical modeling. Methods We conducted retrospective, observational at Luigi Sacco Hospital (Milan, Italy), analyzing 3,344 COVID-19 patients from two pandemic waves (2020–2021). Participants included 1,537 outpatients ARCOVID clinic 1,807 hospitalized patients. was defined based on WHO NICE criteria, as well alternative definitions: 3 6 months post-infection. used bivariate censored Probit model account estimate adjusted prevalence. Results varied 67.4% (WHO), 76.3% (NICE), 80.2% (3 months), 79.6% (6 months). Adjusted remained consistent definitions. The most common were fatigue (58.6%), dyspnea (41.1%), joint/muscle pain (39.2%). Risk factors female sex (OR 2.165–2.379), metabolic disease 1.587–1.629), older age (40–50 years, OR 1.847). Protective antiplatelets 0.640–0.689), statins 0.616), hypoglycemics 0.593–0.706). Vaccination, hydroxychloroquine, antibiotics associated an increased risk LC. Selection significantly influenced estimates, underscoring need robust adjustments. Discussion Our findings highlight high LC, particularly among specific subgroups, strong effects influencing outpatient participation. Differences emphasize impact designs research. identification protective supports targeted interventions patient management strategies. Conclusion provides one comprehensive analyses while accounting bias. call standardized definitions, improved epidemiological methodologies, prevention Future research should explore prospective cohorts refine investigate long-term health outcomes.

Язык: Английский

---

‘The efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID’ – Author’s reply

Clinical Microbiology and Infection, Год журнала: 2024, Номер 30(12), С. 1618 - 1619

Опубликована: Авг. 6, 2024

Язык: Английский

---

Neutralizing VHH Antibodies Targeting the Spike Protein of PEDV

Veterinary Sciences, Год журнала: 2024, Номер 11(11), С. 533 - 533

Опубликована: Ноя. 1, 2024

Porcine epidemic diarrhea virus (PEDV) is a highly contagious coronavirus that infect pigs' intestinal epithelial cells, causing high morbidity and mortality. Due to the rapid mutation of PEDV, vaccine efficacy uncertain, prompting exploration alternative treatments. Nanobodies, also known as variable heavy chain domains chain-only antibodies (VHHs), offer significant potential in biomedical applications due their small size specificity. In this study, yeast two-hybrid technology was employed screen for eight specific VHH sequences targeting PEDV S protein from synthetically constructed nanobody library. The genes were then cloned into expression plasmids recombinant production, resulting VHHs (termed S-VHHs) purified. Indirect immunofluorescence assay (IFA) Western blotting analysis confirmed these specifically bind both its protein. Neutralization assays demonstrated seven S-VHHs exhibited potent neutralizing activity against PEDV. Additionally, combination showed enhanced antiviral effects. Preliminary predictions made regarding binding sites between described study hold candidates prevention treatment infection.

Язык: Английский

---

Re: ‘The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID-19’ by Sun et al.

Clinical Microbiology and Infection, Год журнала: 2024, Номер 30(12), С. 1616 - 1617

Опубликована: Июль 26, 2024

Язык: Английский

---